Diseases & Conditions
Grants & Contracts
News & Events
The ACTG NL consists of Core Laboratory groups in immunology, pharmacology, virology and TB.
The Chemistry Center for Combating Antibiotic-Resistant Bacteria (CC4CARB) is a NIAID-led partnership with RTI International, which oversees the design, synthesis, and management of external investigator-submitted libraries of chemical compounds specifically targeting Gram-negative bacteria.
The Filariasis Research Reagent Resource Center (FR3) maintains oversight of filarial parasites, SOPs, and molecular reagents. FR3 is comprised of two divisions: The Parasite Resource Division and the Molecular Resources Division.
The Markedly Accelerating Research with Knowledge of Tuberculosis Biomarkers (MARK-TB) has created a collaborative biobank in order to accelerate the development of new drugs and treatments for tuberculosis by validating and exploring biomarkers of response to TB drug treatments. The biobank will
The National Institutes of Health (NIH) HIV Reagent Program provides critical research reagents and resources to the scientific community.
This core serves as a national resource for the long-term care and study of animals after irradiation, since 2007. The Radiation Late Effects Program facilitates the conduct of late-stage preclinical studies of mitigators of radiation damage in nonhuman primates.
The Primary Immunodeficiency (PI) Diseases Registry collects validated data on all PI diagnoses from patients who give Informed Consent. The de-identified data in the registry is freely disseminated to those with research questions about PI diseases.
TrialShare is a transformative approach to data-sharing that enables clinical trial transparency.
The USIDNET Cell Repository, part of the US Immunodeficiency Network, provides a resource of DNA and functional lymphoid cells obtained from patients with various primary immunodeficiency diseases.